Jeffrey P. Henderson, M.D., Ph.D.

Associate Professor
Internal Medicine
Infectious Diseases
Molecular Microbiology
Center for Women's Infectious Diseases (cWIDR)

Biochemistry, Biophysics, and Structural Biology Program
Molecular Microbiology and Microbial Pathogenesis Program

  • 314-747-0240

  • 314-747-0061

  • 314-362-1232

  • 8051

  • 10306 BJC Institute of Health

  • jhenderson@dom.wustl.edu

  • http://jphenderson1.wix.com/henderson-lab-site

  • bacterial pathogenesis, host-pathogen interactions, iron, mass spectrometry, medicinal chemistry, metabolomics

  • Biochemical interactions between humans and bacteria in health and disease

Research Abstract:

Growing levels of antibiotic resistance make infection caused by Gram negative bacteria a looming public health crisis. The Henderson laboratory uses interdisciplinary approaches to better understand Gram negative virulence and to identify new therapeutic strategies. To do this, we combine patient-oriented studies with new biochemical approaches to identify how virulence-associated bacterial pathogens cause disease. New mathematic approaches to genetic and metabolomic data suggest that distinct evolutionary virulence “strategies” used by a single pathogenic species may manifest as the same disease. Using these results as a guide, we seek a mechanistic understanding of how these virulence-associated properties interact with the host. Of particular interest are multifunctional small molecules associated with iron scavenging – called siderophores. New properties and host interactions have been identified for bacterial siderophores using a combination of biochemical and pathophysiologic approaches including mass spectrometry-based metabolomics, bacterial genetics, protein chemistry, and infection models. Together, these studies are suggesting new therapeutic and diagnostic strategies directed toward Gram negative bacterial infections.

Selected Publications:

Ohlemacher, S.I., Giblin, D.E., d’Avignon, D., Stapleton, A.E., Trautner, B.W., Henderson, J.P. “Enterobacteria secrete an inhibitor of Pseudomonas virulence during clinical bacteriuria”. Journal of Clinical Investigation, Sept 25, 2017

Koh, E.I., Robinson, A.E., Bandara, N., Rogers, B.E., Henderson, J.P. “Copper import in Escherichia coli by the yersiniabactin metallophore system”. Nature Chemical Biology,13(9):1016-1021. 2017.

Koh, E.I., Hung, C.S., Henderson, J.P. “The yersiniabactin-associated ATP binding cassette proteins YbtP and YbtQ enhance E. coli fitness during high titer cystitis”. Infection and Immunity, 84(5):1312-9, 2016.

Shields-Cutler, R.R., Crowley, J.R., Hung, C., Stapleton, A.E., Aldrich, C.C., Marschall, J., Henderson, J.P. “Human Urinary Composition Controls Siderocalin’s Antibacterial Activity”. Journal of Biological Chemistry, 291(50):25901-25910. 2015.

Koh E.I., Hung C., Parker K.S., Crowley J.R., Giblin, D.E., Henderson, J.P. “Metal selectivity by the virulence-associated yersiniabactin metallophore system”. Metallomics. 7(6):1011-22. 2015.

Lv, H., Hung, C., Henderson, J.P. “Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic Escherichia coli” J. Proteome Research, 13(3):1397-404. 2014.

Parker, K.S., Wilson, J., Marschall, J., Mucha, P.J., Henderson, J.P. “Network analysis reveals sex- and antibiotic resistance-associated antivirulence targets in clinical uropathogens”. ACS Infectious Diseases, 1 (11): 523–532, 2015.

Chaturvedi, K.S., Hung, C., Giblin, D.E., Austin, A.M., Dinauer, M.C., Gross, M.L., Henderson, J.P. “Cupric yersiniabactin is a Virulence-Associated Superoxide Dismutase Mimic”, ACS Chemical Biology, 9(2):551-61. 2013.

Chaturvedi, K.S., Hung, C., Crowley, J.R., Stapleton, A.E., Henderson, J.P. “The siderophore yersiniabactin protects uropathogenic Escherichia coli from copper toxicity in vivo”. Nature Chemical Biology, 8, 731–736. 2012.

Marschall, J., Zhang, L., Foxman, B., Warren, D.K., Henderson, J.P., “Both Host and Pathogen Factors Predispose to Escherichia coli Urinary-Source Bacteremia in Hospitalized Patients”. Clinical Infectious Diseases, 54(12):1692-1698. 2012.

Last Updated: 10/2/2017 8:38:20 AM

Back To Top

Follow us: